$REPL
Replimune Group, Inc. Stock $repl

$repl Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000173795323000009 Filed on May 18, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.21M	$15.04M	$50.20M
YoY Change	33.45%	46.71%	29.47%
% of Gross Profit
Research & Development	$40.44M	$37.44M	$126.5M
YoY Change	37.18%	76.43%	59.06%
% of Gross Profit
Depreciation & Amortization	$621.0K	$528.0K	$2.400M
YoY Change	0.16%	-3.83%	11.78%
% of Gross Profit
Operating Expenses	$55.65M	$53.00M	$177.1M
YoY Change	36.14%	65.67%	49.67%
Operating Profit	-$55.65M		-$177.1M
YoY Change	36.14%		49.67%
Interest Expense	$4.527M	$4.307M	$5.846M
YoY Change	-2266.03%	-1120.62%	-418.93%
% of Operating Profit
Other Income/Expense, Net	$6.294M	-$263.0K	$3.084M
YoY Change	-557.08%	-136.83%	1009.35%
Pretax Income	-$49.35M	-$48.95M	-$174.0M
YoY Change	16.81%	54.44%	500.3%
Income Tax	$200.0K	$288.0K	$300.0K
% Of Pretax Income
Net Earnings	-$49.60M	-$49.24M	-$174.3M
YoY Change	17.26%	55.35%	47.71%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.75		-$2.99
Diluted Earnings Per Share	-$0.75	-$0.75	-$2.99
COMMON SHARES
Basic Shares Outstanding	57.78M shares	56.65M shares	58.21M shares
Diluted Shares Outstanding	66.37M shares		58.21M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$539.1M	$583.4M	$583.4M
YoY Change	36.45%	47.45%	47.45%
Cash & Equivalents	$106.5M	$146.6M	$146.6M
Short-Term Investments	$432.6M	$436.8M	$436.8M
Other Short-Term Assets	$7.895M	$6.278M	$6.278M
YoY Change	95.42%	19.19%	19.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$550.0M	$592.6M	$592.6M
YoY Change	36.84%	46.69%	46.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.616M	$7.479M	$52.35M
YoY Change	-7.87%	-5.72%	-5.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.636M	$1.636M	$1.636M
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$53.85M	$53.99M	$53.99M
YoY Change	-6.32%	-5.64%	-5.64%
TOTAL ASSETS
Total Short-Term Assets	$550.0M	$592.6M	$592.6M
Total Long-Term Assets	$53.85M	$53.99M	$53.99M
Total Assets	$603.9M	$646.6M	$646.6M
YoY Change	31.44%	40.2%	40.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.883M	$5.364M	$5.364M
YoY Change	8.95%	43.73%	43.73%
Accrued Expenses	$21.70M	$22.83M	$22.83M
YoY Change	77.86%	73.7%	73.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.658M	$2.639M	$2.639M
YoY Change	2.98%	3.01%	3.01%
Total Short-Term Liabilities	$32.24M	$33.83M	$33.83M
YoY Change	58.72%	62.96%	62.96%
LONG-TERM LIABILITIES
Long-Term Debt	$52.75M	$28.65M	$52.61M
YoY Change	116.98%	17.38%	115.57%
Other Long-Term Liabilities	$578.0K	$472.0K	$4.861M
YoY Change	-87.27%	-90.17%	1.25%
Total Long-Term Liabilities	$578.0K	$29.12M	$57.47M
YoY Change	-98.0%	-0.3%	96.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.24M	$33.83M	$33.83M
Total Long-Term Liabilities	$578.0K	$29.12M	$57.47M
Total Liabilities	$89.86M	$91.30M	$91.30M
YoY Change	82.78%	82.73%	82.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$535.0M	-$485.5M
YoY Change	51.34%	56.01%
Common Stock	$57.00K	$57.00K
YoY Change	16.33%	21.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$514.0M	$555.3M	$555.3M
YoY Change
Total Liabilities & Shareholders Equity	$603.9M	$646.6M	$646.6M
YoY Change	31.44%	40.2%	40.2%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2023
OPERATING ACTIVITIES
Net Income	-$49.60M	-$49.24M	-$174.3M
YoY Change	17.26%	55.35%	47.71%
Depreciation, Depletion And Amortization	$621.0K	$528.0K	$2.400M
YoY Change	0.16%	-3.83%	11.78%
Cash From Operating Activities	-$48.59M	-$32.80M	-$128.1M
YoY Change	45.23%	45.39%	55.82%
INVESTING ACTIVITIES
Capital Expenditures	$449.0K	$251.0K	$2.270M
YoY Change	-57.96%	-121.79%	-2.83%
Acquisitions
YoY Change
Other Investing Activities	$7.810M	-$22.50M	-$140.2M
YoY Change	22.36%	608.92%	-26558.87%
Cash From Investing Activities	$7.361M	-$22.75M	-$142.5M
YoY Change	38.49%	425.94%	7790.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$149.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.105M	-77.00K	$311.3M
YoY Change	-96.6%	-121.45%	4618.14%
NET CHANGE
Cash From Operating Activities	-$48.59M	-32.80M	-$128.1M
Cash From Investing Activities	$7.361M	-22.75M	-$142.5M
Cash From Financing Activities	$1.105M	-77.00K	$311.3M
Net Change In Cash	-$40.11M	-55.63M	$40.64M
YoY Change	-736.95%	109.72%	-153.08%
FREE CASH FLOW
Cash From Operating Activities	-$48.59M	-$32.80M	-$128.1M
Capital Expenditures	$449.0K	$251.0K	$2.270M
Free Cash Flow	-$49.04M	-$33.05M	-$130.3M
YoY Change	42.04%	54.39%	54.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2100000	usd
CY2023	dei	Local Phone Number LocalPhoneNumber	222-9600
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001737953
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38596
CY2023	dei	Entity Registrant Name EntityRegistrantName	REPLIMUNE GROUP, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2082553
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	500 Unicorn Park Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 303
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	REPL
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Public Float EntityPublicFloat	486900000	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57775993	shares
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146590000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	105948000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	436796000	usd
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	289707000	usd
CY2023Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2939000	usd
CY2022Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	3055000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6278000	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5267000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	592603000	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	403977000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7479000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	usd
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1636000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5208000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	39665000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	usd
CY2023Q1	us-gaap	Assets Assets	646591000	usd
CY2022Q1	us-gaap	Assets Assets	461192000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5364000	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3732000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24704000	usd
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1118000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2639000	usd
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	33825000	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20756000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4389000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23965000	usd
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28648000	usd
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	472000	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q1	us-gaap	Liabilities Liabilities	91299000	usd
CY2022Q1	us-gaap	Liabilities Liabilities	49963000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56676313	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56676313	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47338660	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47338660	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	47000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1034994000	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	723359000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485488000	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-311204000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5729000	usd
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-973000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	555292000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646591000	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	461192000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	126527000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79545000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	50553000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38769000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	177080000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	118314000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-177080000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-118314000	usd
CY2023	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	2914000	usd
CY2022	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	3170000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	10006000	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	390000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2197000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2223000	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1963000	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5676000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1059000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3084000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	278000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-173996000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-118036000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-174284000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118036000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.99
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58213010	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58213010	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52212269	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52212269	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-174284000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118036000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5483000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	748000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1219000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1327000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-167582000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-118615000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	498728000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	748000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1327000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6862000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24254000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118036000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	411229000	usd
CY2023	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	92778000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	149854000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5483000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1219000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3444000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28131000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-174284000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	555292000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-174284000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-118036000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	28131000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2447000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2147000	usd
CY2023	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	5638000	usd
CY2022	repl	Net Amortization Of Premiums And Discounts On Short Term Investments NetAmortizationOfPremiumsAndDiscountsOnShortTermInvestments	-2220000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	494000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5676000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	61000	usd
CY2022	repl	Increase Decrease In Research And Development Incentives Receivable IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable	247000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1059000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	815000	usd
CY2023	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-225000	usd
CY2022	repl	Increase Decrease Operating Lease Right Of Use Asset IncreaseDecreaseOperatingLeaseRightOfUseAsset	-99000	usd
CY2023	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-2428000	usd
CY2022	repl	Increase Decrease Finance Lease Right Of Use Asset IncreaseDecreaseFinanceLeaseRightOfUseAsset	-2428000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1981000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1118000	usd
CY2023	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	11376000	usd
CY2022	repl	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	4725000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-238000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-73000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	472000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-128050000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82180000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2270000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2336000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	583412000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	255720000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	443180000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	256250000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142502000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1806000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149854000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	92778000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2023	repl	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	37438000	usd
CY2022	repl	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	28154000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	365000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	264000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3444000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6862000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	311303000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6598000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-109000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	818000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40642000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-76570000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107584000	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184154000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148226000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107584000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1066000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	103000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	415000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	290000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	363000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	Nature of the business<div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replimune Group, Inc. (the “Company”) is a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies to treat cancer. Replimune Group, Inc., whose predecessor was founded in 2015, is the parent company of its wholly owned, direct and indirect subsidiaries: Replimune Limited (“Replimune UK”); Replimune, Inc. (“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company has incurred recurring losses since its inception, including net losses of $174.3 million and $118.0 million for the years ended March 31, 2023 and 2022, respectively. In addition, as of March 31, 2023, the Company had an accumulated deficit of $485.5 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of these consolidated financial statements, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.</span></div>
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-174300000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-118000000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-485500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances.</span></div>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	121500000	usd
CY2022Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	75100000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7242000	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4795000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7479000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	usd
CY2023	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	2900000	usd
CY2022	repl	Research And Development Incentives Income ResearchAndDevelopmentIncentivesIncome	3200000	usd
CY2023Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	2900000	usd
CY2022Q1	repl	Research And Development Incentives Receivable Current ResearchAndDevelopmentIncentivesReceivableCurrent	3100000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5500000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1200000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	700000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1300000	usd
CY2023	repl	Minimum Percentage Of Income Tax Benefit Realized Upon Ultimate Settlement MinimumPercentageOfIncomeTaxBenefitRealizedUponUltimateSettlement	0.50
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14721000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12728000	usd
CY2023Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	11261000	usd
CY2022Q1	repl	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	5882000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	9909000	usd
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5569000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	540000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	621000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2994000	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1320000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24704000	usd
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13392000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85600000	usd
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107800000	usd
CY2020Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270000000	usd
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	242600000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	28131000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	28131000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	24254000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	82500	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6514334	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.78
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	30358000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1604489	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	19.02
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	296876	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	367119	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	21.30
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7454828	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.24
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M17D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31244000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4725073	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.43
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M4D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	28570000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7454828	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	17.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y10M17D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	31244000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	34800000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.80
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.40
CY2023	repl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	2700000	usd
CY2022	repl	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	16200000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.26
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-174284000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-118036000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58213010	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58213010	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	52212269	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	52212269	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.99
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.26
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7952172	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7011678	shares
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2428000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2428000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2197000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2223000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1018000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1003000	usd
CY2023	us-gaap	Lease Cost LeaseCost	5643000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5654000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	2969000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1118000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2639000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due Next Twelve Months OperatingAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	3757000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1150000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	2718000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due Year Two OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo	3868000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1159000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	2799000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due Year Three OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree	3958000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1126000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	2883000	usd
CY2023Q1	repl	Operating Finance Lease Liability Payments Due Year Four OperatingFinanceLeaseLiabilityPaymentsDueYearFour	4009000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1077000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueYearFive	4046000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1905000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	35053000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due After Year Five OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFive	36958000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7535000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	49061000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Payments Due OperatingAndFinanceLeaseLiabilityPaymentsDue	56596000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2028000	usd
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	22457000	usd
CY2023Q1	repl	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	24485000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5507000	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	26604000	usd
CY2023Q1	repl	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	32111000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5208000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5552000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	39665000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	42094000	usd
CY2023Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	44873000	usd
CY2022Q1	repl	Lease Right Of Use Asset LeaseRightOfUseAsset	47646000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1118000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1070000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2639000	usd
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2562000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4389000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4801000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	23965000	usd
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	24406000	usd
CY2023Q1	repl	Lease Liability LeaseLiability	32111000	usd
CY2022Q1	repl	Lease Liability LeaseLiability	32839000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1014000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	968000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2197000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2223000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	365000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	264000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	290000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	363000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P16Y3M18D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y3M18D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.103
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.101
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.083
CY2023Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	1000000	usd
CY2022Q1	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	2000000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.311
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18367000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-28985000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-155629000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-89051000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-173996000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-118036000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.015
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.01
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.018
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.015
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.060
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.106
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.236
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	93788000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61112000	usd
CY2023Q1	repl	Research And Development Credits ResearchAndDevelopmentCredits	0	usd
CY2022Q1	repl	Research And Development Credits ResearchAndDevelopmentCredits	1000000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4535000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4367000	usd
CY2023Q1	repl	Deferred Tax Assets Capitalization Of Start Up Cost DeferredTaxAssetsCapitalizationOfStartUpCost	1301000	usd
CY2022Q1	repl	Deferred Tax Assets Capitalization Of Start Up Cost DeferredTaxAssetsCapitalizationOfStartUpCost	1286000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14757000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8922000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2906000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	1452000	usd
CY2023Q1	repl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7964000	usd
CY2022Q1	repl	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7309000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	24000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	310000.00	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	125275000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	85758000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	113889000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74892000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	11386000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	10866000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	11386000	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	10866000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11386000	usd
CY2022Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10866000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74892000	usd
CY2021Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40028000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	41063000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36679000	usd
CY2023	repl	Valuation Allowance Deferred Tax Asset Increase Decrease Recorded To Income Tax Provision For Equity Amount ValuationAllowanceDeferredTaxAssetIncreaseDecreaseRecordedToIncomeTaxProvisionForEquityAmount	-2066000	usd
CY2022	repl	Valuation Allowance Deferred Tax Asset Increase Decrease Recorded To Income Tax Provision For Equity Amount ValuationAllowanceDeferredTaxAssetIncreaseDecreaseRecordedToIncomeTaxProvisionForEquityAmount	-1815000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	113889000	usd
CY2022Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74892000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	8757000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8757000	usd
CY2022Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	repl	Number Of Operating Geographic Regions NumberOfOperatingGeographicRegions	2	region
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7479000	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7933000	usd

Files In Submission

Name	View Source	Status
0001737953-23-000009-index-headers.html	Edgar Link	pending
0001737953-23-000009-index.html	Edgar Link	pending
0001737953-23-000009.txt	Edgar Link	pending
0001737953-23-000009-xbrl.zip	Edgar Link	pending
exhibit211_replimunexsubsi.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
lease-68ghinnovationdrivem.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
repl-20220331x10kxex43.htm	Edgar Link	pending
repl-20230331.htm	Edgar Link	pending
repl-20230331.xsd	Edgar Link	pending
repl-20230331x10kxex312.htm	Edgar Link	pending
repl-20230331x10kxex321.htm	Edgar Link	pending
repl-20230331x10kxex322.htm	Edgar Link	pending
repl-20230331x10kxexx311.htm	Edgar Link	pending
repl-20230331_g1.jpg	Edgar Link	pending
repl-20230331_def.xml	Edgar Link	unprocessable
repl-20230331_htm.xml	Edgar Link	completed
replimunefy23consentforex2.htm	Edgar Link	pending
replimunegroupinc-induceme.htm	Edgar Link	pending
replimunegroupinc-restrict.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
repl-20230331_cal.xml	Edgar Link	unprocessable
repl-20230331_lab.xml	Edgar Link	unprocessable
repl-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REPL
Replimune Group, Inc. Stock $repl

2023 Q2 Form 10-K Financial Statement

#000173795323000009 Filed on May 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL Replimune Group, Inc. Stock $repl

2023 Q2 Form 10-K Financial Statement

#000173795323000009 Filed on May 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REPL
Replimune Group, Inc. Stock $repl